
Your Feed
Use of Biomarkers to Predict CAR-T Outcomes | Darren Pan, MD | ASH 2023
Fighting DLBCL by Attacking the Microenviroment | Leandro Cerchietti, MD | ASH 2023
Effects of Stem Cell Infusion with BCMA CAR-T | Meera Mohan, MD | ASH 2023
Real World Teclistamab Results for Relapsed Refractory Myeloma Patients | Meera Mohan, MD | ASH 2023
Moving Towards Immunotherapy for Newly Diagnosed DLBCL Patients | Paolo Strati, MD | ASH 2023
Updates to Management of CAR-T and Teclistamab for Myeloma Patients | Radhika Bansal, MD | ASH 2023
iStopMM Trial in Iceland #myeloma | Jón Þórir Óskarsson, MSc | ASH 2023
Impact of Financial Toxicity and Time Toxicity in Myeloma QOL | Rahul Banerjee, MD, FACP | ASH 2023
Real-World Bortezomib Patterns in Newly Diagnosed Myeloma | Gurbakhash Kaur, MD, MA | ASH 2023
Fine Particulate Matter and Myeloma Outcomes in Urban Cohort | Michael Wysota, MD | ASH 2023
Genomic Profiling in High-Risk Smoldering Myeloma | Benjamin Diamond, MD | ASH 2023
Dexamethasone Dose Strength Impact in Newly Diagnosed Myeloma | Rahul Banerjee, MD, FACP | ASH 2023
CAR-T in Myeloma Patients with Extramedullary and Paramedullary Disease | Darren Pan, MD | ASH 2023




